Lini joined Shattuck Labs in July 2017 as Chief Medical Officer. She brings more than 25 years of academic, medical, and pharmaceutical experience. Her broad oncology drug development expertise spans early-to-late phase development from Pre-IND through registration and commercialization. Prior to joining Shattuck, Lini was Head of Global Clinical Development and Senior Vice President at Adaptimmune, responsible for clinical development of the company’s immuno-oncology pipeline. She spent several years with GlaxoSmithKline (GSK) culminating her tenure as, Vice President R&D and Head Unit Physician for Oncology. While at GSK, Lini was instrumental in leading the development of several compounds. Lini practiced medicine in both the United Kingdom and the United States and is Board Certified in Hematology and Oncology. Lini was an attending physician at Dana Farber Cancer Institute in Boston and at Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital in Miami and held academic appointments at Harvard University and the University of Miami. She received her medical degree from The University of Liverpool, England and a Master’s in Business Administration from the Fuqua School of Business at Duke University.